Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blinded, Placebo-controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of BBP-711 (ORF-229) in Healthy Adult Subjects

NCT04876924 is registered in ClinicalTrials.gov with Cantero Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT04876924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04876924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blinded, Placebo-controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of BBP-711 (ORF-229) in Healthy Adult Subjects
Lead sponsor
Cantero Therapeutics, a BridgeBio company
Phase
Phase 1
Overall status
Completed
Start date
April 29, 2021
Completion date
February 27, 2022
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy